IP Library Granted Patent US 7,465,711
Granted Patent B2
US 7,465,711 · App. 11/704,393 · Granted Dec 16, 2008

Treatment of cancers of lymphocytic cells with product R

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,465,711
App. No.
11/704,393
Granted
Dec 16, 2008
Kind
B2
Abstract

A method of treating a patient suffering from cancers of lymph cells such as acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma comprises parenterally administering to said patient an effective acute lymphocytic leukemia treatment amount of Product R in a pharmaceutically acceptable formulation.

Claims (9)

1. A method of shrinking enlarged lymph nodes in patients with Hodgkin's disease or Non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective amount of Product R for shrinking lymph nodes in a pharmaceutically acceptable formulation.

2. The method of claim 1 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.

3. The method of claim 1 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.

4. A method of shrinking enlarged spleen in patients with Hodgkin's disease or Non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective amount of Product R for shrinking spleen in a pharmaceutically acceptable formulation.

5. The method of claim 4 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.

6. The method of claim 4 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.

7. A method of treating body wasting, loss of appetite and fatigue in patients suffering from acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, comprising parenterally adminstereing to said patient an effective amount of Product R in a pharmaceutically acceptable formulation.

8. The method of claim 7 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.

9. The method of claim 7 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.

Assignments (4)
SECURITY AGREEMENT Recorded May 20, 2009
From: BBM HOLDINGS, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 022708/0679 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 022542 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE OWNERSHIP TRANSFERED FROM ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC. TO BBM HOLDINGS, INC. Recorded Apr 30, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: BBM HOLDINGS, INC.
Reel/Frame 022629/0569 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR/ASSIGNEE NAMES PREVIOUSLY RECORDED ON REEL 022510 FRAME 0187. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNORS ARE ADVANCED VIRAL RESEARCH CORP. AND TRIAD BIOTHERAPEUTICS, INC., AND THE ASSIGNEE IS YA GLOBAL INVESTMENTS, L.P. Recorded Apr 14, 2009
From: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
To: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
Reel/Frame 022542/0001 →
FORECLOSURE BY THIRD PARTY Recorded Apr 6, 2009
From: YA GLOBAL INVESTMENTS, L.P. (F/K/A CORNELL CAPITAL PARTNERS, L.P.)
To: ADVANCED VIRAL RESEARCH CORP.; TRIAD BIOTHERAPEUTICS, INC.
Reel/Frame 022510/0187 →